WuXi NextCODE strikes deal to sequence and share 1,000 cancer genomes

WuXi NextCODE has struck another sequencing agreement. The latest deal will see the service provider sequence samples taken from 1,000 cancer patients in San Antonio, TX. Phase I clinical trial specialist South Texas Accelerated Research Therapeutics plans to link the genome data to patient records using Medidata ($MDSO) Rave, before making the resource available to researchers and clinicians. Release | Article